Trial Profile

A phase 1b trial to evaluate the safety, feasibility, and preliminary efficacy of NOUS PEV in combination with the anti-PD-1 checkpoint inhibitor pembrolizumab for treatment of patients with either locally advanced 1L melanoma or 1L non-small cell lung cancer (NSCLC)

Status: Planning

Phase of Trial: Phase I

Latest Information Update: 19 Apr 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs NOUS PEV (Primary) ; Pembrolizumab (Primary)
Indications Malignant melanoma; Non-small cell lung cancer; Urogenital cancer
Focus Adverse reactions
Sponsors Nouscom

15 Apr 2021 According to a Nouscom media release, the company has received the regulatory approval for this study.
10 Dec 2020 According to a Nouscom media release, this study will begin in 1Q 2021.
26 Feb 2020 According to a Nouscom media release, the company expects to initiate clinical studies later in 2020.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com